9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris. Mark Mascolini
|
|
- Ralph Oswald Sullivan
- 6 years ago
- Views:
Transcription
1 Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial 9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris Mark Mascolini A high proportion of 165 people who switched from a stable boosted protease inhibitor (PI) to raltegravir/etravirine (RAL/ETV) maintained virologic suppression through 48 weeks in a French trial enrolling people 45 or older [1]. Seven participants stopped the regimen because of adverse events, and 1 with a prior nonnucleoside mutation had virologic failure. The search is on for a safe two-antiretroviral combination that can maintain HIV control achieved with more complex or toxic regimens. French ANRS investigators aiming to replace a ritonavir-boosted PI regimen in older adults nominated RAL/ETV (an integrase inhibitor and a nonnucleoside) as their candidate maintenance medley. The objective of the ANRS-163 ETRAL trial was to evaluate RAL/ETV after a stable boosted PI for its ability to maintain virologic control [2], defined as absence of two consecutive loads above 50 copies through 48 weeks. Enrolling 160 participants, the ANRS team expected a maximum of 8 virologic failures in 48 weeks. The investigators recruited people at least 45 years old who maintained a viral load below 50 copies for at least 2 years and took a current boosted PI regimen. No one had taken an integrase inhibitor (such as raltegravir) or etravirine, and no one had resistance to either study drug at any time. All participants traded their PI combination for RAL/ETV at a dose of 400/200 mg twice daily. The primary endpoint was proportion with a viral load below 50 copies through 48 weeks. Among 170 participants, 5 never started RAL/ETV and were not included in the analysis. Median age of the 165 participants stood at 52 years (interquartile range 48 to 58), 75% were white, 71% were men, and 40% were men who have sex with men. Enrollees had taken antiretroviral therapy for a median of 16.8 years. Two thirds of participants (65%) were taking a boosted PI plus two nucleosides, 21% were taking boosted-pi monotherapy, 7% were taking a boosted PI plus a nonnucleoside, and the rest were taking other combinations. Three quarters (73%) had a once-daily baseline regimen. By week 48 only 1 participant had virologic failure, and this person turned out to have a previous nonnucleoside mutation, K103N. Three additional nonnucleoside mutations emerged with this failure. The participant regained viral control after resuming the baseline regimen. Thus the 48- week virologic success rate was 99.4% (95% confidence interval [CI] 95.6 to 99.9). Nine participants (5%) had isolated blips above 50 copies/ml, none of whom had detectable raltegravir or etravirine mutations as a result. In addition to the 1 virologic failure, there were 7 therapeutic failures due to adverse events to yield a therapeutic success rate of 94.5% (95% CI 89.8 to 97.1). Among 19 serious adverse events, researchers rated 4 related to study drugs, including agitation with a persecutory delusion,
2 hepatic cytolysis, postherpetic neuralgia, and hyperglycemia/malaise. Baseline parameters that improved significantly through 48 weeks were CD4/CD8 ratio (+0.05), total cholesterol (-0.25 mmol/l), HDL cholesterol (+0.09 mmol/l), LDL cholesterol (-0.21 mmol/l), non-hdl cholesterol (-0.35 mmol/l), and triglycerides (-0.32 mmol/l) (all P < 0.02). Continuing follow-up will include assessments of bone markers, inflammation markers, and fat tissue. Despite twice-daily dosing with RAL/ETV, the ANRS team calculated an adherence rate above 95%. References 1. Katlama C, Reynes J, Assoumou L, et al. Raltegravir/etravirine as maintenance strategy in HIV-1-infected virologically suppressed individuals aged over 45 years on prior boosted protease inhibitor containing regimen: results at W48 of the ANRS163-ETRAL study. 9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris. Abstract MOPEB ClinicalTrials.gov. Capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age--anrs 163 ETRAL. ClinicalTrials.gov identifier NCT Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial C Katlama 1, J Reynes 2, L Assoumou 3, MA Valantin 1, L Béniguel 3, C Soulié 4, O Bouchaud 5, F Raffi 6, E Martinez 7, AL Argoud 8, S Gibowski 8, G Peytavin 9, AG Marcelin 4, D Costagliola 3 1 APHP hôpital Pitié Salpêtrière, Sorbonne Universités, INSERM, UPMC Univ Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France ; 2 CHU de Montpellier et UMI IRD233- INSERM U1175-Université de Montpellier ; 3 Sorbonne Universités, INSERM, UPMC Univ Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France ; 4 Laboratoire de Virologie, Sorbonne Universités, INSERM, UPMC Univ Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France ; 5 APHP hôpital Avicenne et Université Paris 13, IMEA-Fondation Internationale Léon Mba ; 6 University Hospital Hotel Dieu- Nantes, France; 7 Infectious Diseases Unit Hospital Clínic - IDIBAPS University of Barcelona, Barcelona, Spain; 8 ANRS, France Recherche Nord & Sud Sida-HIV Hépatites, Paris, France ; 9 AME, Inserm UMR 1137, Université Paris 7, UF 301 Laboratoire de Pharmaco- Toxicologie, GH X Bichat-Cl Bernard, Paris, France
3
4
5
6
7
8
9
10
11
Pr Vincent Calvez. Faculté de Médecine Sorbonne Université UMR Sorbonne Université Inserm 1136 Service de Virologie Hôpital Pitié-Salpêtrière
Pr Vincent Calvez Faculté de Médecine Sorbonne Université UMR Sorbonne Université Inserm 1136 Service de Virologie Hôpital Pitié-Salpêtrière Pretreatment HIV Drug Resistance in the START Study Using Next
More informationPersistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome
J Antimicrob Chemother 2012; 67: 2231 2235 doi:10.1093/jac/dks191 Advance Access publication 29 May 2012 Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationAntiviral Therapy 2012; 17: (doi: /IMP2093) UPMC Université de Paris 06, UMR_S938, INSERM, CDR Saint-Antoine, Paris, France 2
Antiviral Therapy 2012; 17:915 919 (doi: 10.3851/IMP2093) Short communication Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled
More informationTitle: Usefulness of Kaposi sarcoma-associated herpesvirus (KSHV)-DNA viral. load in whole blood for the diagnosis and monitoring of KSHV-associated
JCM Accepted Manuscript Posted Online 11 April 2018 J. Clin. Microbiol. doi:10.1128/jcm.00569-18 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 2 3 Title: Usefulness of Kaposi
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationAntiviral Therapy 14:
Antiviral Therapy 14:451 457 Short communication CD4 + T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4 + T-cell counts >200 cells/mm
More informationWhat to look for in a paper?
What to look for in a paper? D Costagliola Institut Pierre Louis d épidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, INSERM Disclosures I have received consultancy fees, honoraria,
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationAntiviral Therapy 2015; 20: (doi: /IMP2949)
Antiviral Therapy 2015; 20:655 660 (doi: 10.3851/IMP2949) Short communication Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy
More informationPharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women
Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women DR MINH LÊ PHARMACO-TOXICOLOGY DEPARTMENT APHP, HÔPITAL BICHAT-CLAUDE BERNARD PARIS, FRANCE ABSTRACT #O_01 17TH INTERNATIONAL
More informationPurpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation
ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg
More informationLow-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice
J Antimicrob Chemother 2015; 70: 2347 2353 doi:10.1093/jac/dkv099 Advance Access publication 28 April 2015 Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice
More informationViro-Immunological Response in HIV-1 Infected Patients with Multiple. Treatment Failures Receiving Raltegravir and Optimized Background Therapy,
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Viro-Immunological Response in HIV-1 Infected Patients with Multiple Treatment Failures Receiving Raltegravir and Optimized Background
More informationResponse to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network
Short communication Antiviral Therapy 12:1305 1310 Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network Marie-Laure Chaix 1 *, Loic Desquilbet
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationFrançois Raffi, 1 Christine Katlama, 2 Michael Saag, 3 Martin Wilkinson, 6 Jain Chung, 5 Lynn Smiley, 4 and Miklos Salgo 5
HIV/AIDS MAJOR ARTICLE Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO)
More informationSpontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established?
HIV/AIDS BRIEF REPORT Spontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established? Cécile Goujard, 1,2 Marie-Laure Chaix, 3 Olivier Lambotte, 1,2 Christiane
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationMortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord
Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Laurence WEISS Hôpital Européen Georges Pompidou, Université Paris-Descartes Paris, France Deaths per 100 Person-Years
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationWhat is the virological support for reduced drug regimens?
What is the virological support for reduced drug regimens? Pr Anne-Genevieve Marcelin Pitié-Salpêtrière Hospital UMR 1136 University Pierre et Marie Curie Paris, France Disclosure of Personal and Commercial
More informationOriginal article Pharmacokinetics, safety and efficacy of ritonavir boosted atazanavir (300/100 mg once daily) in HIV 1-infected pregnant women
Antiviral Therapy 2015; 20:507 513 (doi: 10.3851/IMP2936) Original article Pharmacokinetics, safety and efficacy of ritonavir boosted atazanavir (300/100 mg once daily) in HIV 1-infected pregnant women
More information1950 CID 2009:49 (15 December) HIV/AIDS. Received 17 April 2009; accepted 31 July 2009; electronically published 13 November 2009.
HIV/AIDS BRIEF REPORT Long-Term Evolution and Determinants of Renal Function in HIV-Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997 1999, ANRS CO8 APROCO-COPILOTE Catherine
More informationANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C
ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C Head : Nahon Pierre, Service d'hépatologie, Hôpital Jean Verdier Roudot-thoraval Françoise, Service de santé publique,
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationResearch in viral hepatitis: the French ANRS experience
PARIS HEPATITIS CONFERENCE January 14-15, 2013 Research in viral hepatitis: the French ANRS experience Pr. Jean-François DELFRAISSY Director of ANRS Internal Medicine Department CHU Bicêtre Paris XI -
More informationThe BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir
The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects with Virologic Suppression
More informationShort communication Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
Antiviral Therapy 2010 15:1045 1052 (doi: 10.3851/IMP1662) Short communication Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationAIDS Research and Therapy. Open Access RESEARCH
DOI 10.1186/s12981-016-0101-3 AIDS Research and Therapy RESEARCH Open Access Incidence and risk factors for liver enzymes elevations in highly treatment experienced patients switching from enfuvirtide
More informationNon-inferiority trials and switch from non-inferiority to superiority. D Costagliola U 943 INSERM and UPMC Paris 06
Non-inferiority trials and switch from non-inferiority to superiority D Costagliola U 943 INSERM and UPMC Paris 06 References l ICH E 9 et E10 l Points to consider on biostatistical methodological issues
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationEuropean Guidelines. for the Clinical Management and Treatment of HIV Infected Adults
European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion
More informationReceived 31 October 2013; returned 10 November 2013; revised 16 December 2013; accepted 19 December 2013
J Antimicrob Chemother 2014; 69: 1648 1652 doi:10.1093/jac/dkt536 Advance Access publication 16 February 2014 Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients
More informationAbstract #8 15th EU Meeting on HIV & Hepatitis (7-9 June 2017)
Epidemiological study of Doravirine associated resistance mutations in HIV-1- infected treatment-naïve patients from two large databases in France and Italy Anne-Genevieve Marcelin, Maria Mercedes Santoro,
More informationImpact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study Vincent Madelain, Minh Le, Karen Champenois, Charlotte Charpentier, Roland
More informationAntiviral Therapy 2016; 21: (doi: /IMP3024)
Antiviral Therapy 2016; 21:405 412 (doi: 10.3851/IMP3024) Original article Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationPerformance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination
Lusivika-Nzinga et al. BMC Medical Research Methodology (2017) 17:160 DOI 10.1186/s12874-017-0434-1 RESEARCH ARTICLE Open Access Performance of the marginal structural cox model for estimating individual
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationHow France is eliminating HCV and the role of screening strategies
HCV Elimination Mini Policy Summit «Eliminating HCV in Romania» European Parliament, 27 September 2017 How France is eliminating HCV and the role of screening strategies Sylvie Deuffic-Burban, Inserm,
More informationThe Genetic Barrier to Resistance
The Genetic Barrier to Resistance Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Beijing, May 2013 The Genetic Barrier to Resistance The genetic
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More informationBRIEF REPORT: CLINICAL SCIENCE
BRIEF REPORT: CLINICAL SCIENCE Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial Catherine
More informationInvestigator Initiated Study Program (IISP) Project Manager
Alix de Jacquelot alix2j@hotmail.fr Master EUDIPHARM Intern Merck-Sharp&Dohme Project Manager Medical Affairs 3, Avenue Hoche, PARIS Supervised by : Dr Dominique BLAZY dominique_blazy@merck.com Medical
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationActualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis
Actualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis Pr Vincent CALVEZ MD, PhD Dpt of Virology Pitié-Salpêtrière Hospital Paris, France Transmitted Drug Resistance in Low and
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationDr Manisha Yapa. Chelsea and Westminster Hospital, London. 19 th Annual Conference of the British HIV Association (BHIVA)
19 th Annual Conference of the British HIV Association (BHIVA) Dr Manisha Yapa Chelsea and Westminster Hospital, London 16-19 April 2013, Manchester Central Convention Complex The impact of switching to
More informationDOI: /hiv British HIV Association HIV Medicine (2014), 15, SHORT COMMUNICATION
DOI: 10.1111/hiv.12071 SHORT COMMUNICATION Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load 100 000 copies/ml in the pooled ECHO and THRIVE phase 3, randomized,
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationDepartment of General Medicine, Juntendo University School of Medicine, Tokyo; and 2
Jpn. J. Infect. Dis., 69, 33 38, 2016 Original Article Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naäƒve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationAsier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France
Infection à VIH : une rémission possible Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France Viral reservoirs persist in HIV-infected individuals receiving
More informationPneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods
DOI: 10.1111/j.1468-1293.2008.00546.x r 2008 British HIV Association HIV Medicine (2008), 9, 203 207 ORIGINAL RESEARCH Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationAntiviral Therapy 2012; 17: (doi: /IMP2065)
Antiviral Therapy 2012; 17:855 860 (doi: 10.3851/IMP2065) Original article Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected
More informationTime taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART
Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART Authors M A Ismail, E Okpo, S Baguley, A Butt, D Brawley, I Tonna 4 University of Aberdeen, MBChB Office, School
More informationOptimizing the treatment
PIs are the real world answer for: Optimizing the treatment Sergio Lo Caputo Malattie Infettive - Azienda Sanitaria Firenze Evolution of ARVs DARUNAVIR PI ETRAVIRINA NNRTI DOLUTEGRAVIR INI POTENZA E ALTA
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationIntegrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection
Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection Juan Ambrosioni, David Nicolás, Christian Manzardo, Fernando Agüero, José Luis Blanco, Maria del Mar
More informationInvestigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort
Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort A. Lacey 1, W. Tinago 1, E. Alvarez Barco 1, A.J. Macken
More informationHIV DRUG RESISTANCE AND STEWARDSHIP 3 RD LINE PROGRAMME
HIV DRUG RESISTANCE AND STEWARDSHIP 3 RD LINE PROGRAMME SOUTHERN AFRICAN HIV CLINICIANS SOCIETY CONFERENCE - 2014 26 SEPTEMBER 2014 Khadija Jamaloodien Affordable Medicines ANTIMICROBIAL STEWARDSHIP The
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationStribild, a Single Tablet Regimen for the Treatment of HIV Disease
Comb Prod Ther (2013) 3:1 8 DOI 10.1007/s13556-013-0001-y REVIEW Stribild, a Single Tablet Regimen for the Treatment of HIV Disease Cynthia Brinson To view enhanced content go to www.combitherapy-open.com
More informationChanges in cellular HIV DNA levels during the MONET trial: 144 Weeks of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
Changes in cellular HIV DNA levels during the MONET trial: 144 Weeks of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs Anna Maria Geretti, Jose R Arribas, Johan Vingerhoets, Geraldine Foster, Sabine
More informationArticles. Funding Janssen.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationStudy Design. Screening/Enrollment (2:1) Primary endpoint: Determine the proportion of patients with HIV RNA < 50 c/ml at week 24
The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationEuropean AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe
European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe PANEL MEMBERS Nathan Clumeck, Treasurer Chair, Brussels, Belgium Anton Pozniak,
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationMany highly active antiretroviral therapy PROCEEDINGS
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: IS THERE A ROLE FOR QUADRUPLE REGIMENS? * François Raffi, MD, PhD ABSTRACT Although many highly active antiretroviral therapy (HAART)
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationSafety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients
Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients Amy Moore, Sonali Sonecha, Tristan Barber, Anton Pozniak, David Asboe, Marta Boffito
More informationPRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients
PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon 1 ASM Microbe 2016
More informationINTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING
INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING Dr. Danni Kirwan ID/Microbiology SpR St. George s Hospital, London ARV initiation in treatment-naïve patients BHIVA,
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationMiss Jane Rowlands. Chelsea and Westminster Hospital, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Miss Jane Rowlands Chelsea and Westminster Hospital, London 1-4 April 2014, Arena and Convention Centre Liverpool Multi-centre open-label study of switching
More informationSection 3: Introduction to ARVs
Section : Introduction to ARVs Section : Introduction to ARVs.1 Introduction Section is about antiretroviral drugs (ARVs). It includes information about the medical approach to treatment as well as how
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for REZOLSTA This is a summary of the risk management plan (RMP) for REZOLSTA. The RMP details important risks of REZOLSTA,
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationCitation J. Acquir. Immune Defic. Syndr. 2008;48(2): /QAI.0b013e
MSF Field Research Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon Item type Authors Article Kouanfack, Charles; Laurent, Christian; Peytavin, Gilles;
More informationResistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Viruses 2014, 6, 2858-2879; doi:10.3390/v6072858 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical
More informationArticles. Funding Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS), INSERM, and the French Ministry of Health.
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study Marguerite Guiguet, François Boué, Jacques Cadranel,
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for PREZISTA (Darunavir [TMC114]) This is a summary of the risk management plan (RMP) for PREZISTA. The RMP details important
More informationAppendix NEW METHOD FOR ESTIMATING HIV INCIDENCE AND TIME FROM INFECTION TO DIAGNOSIS USING HIV SURVEILLANCE DATA: RESULTS FOR FRANCE
Supporting document 1 Appendix NEW METHOD FOR ESTIMATING HIV INCIDENCE AND TIME FROM INFECTION TO DIAGNOSIS USING HIV SURVEILLANCE DATA: RESULTS FOR FRANCE Ndawinz JDA 1,2, Costagliola D 1,2,3 and Supervie
More information